Targeted Drug Combo vs. Chemo for Advanced Thyroid Cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new combination of targeted drugs (dabrafenib and trametinib) compared to chemotherapy (cabozantinib) for people with a specific type of advanced thyroid cancer called BRAF-mutated differentiated thyroid cancer. The goal is to see which treatment works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- Your thyroid cancer is a type called differentiated thyroid cancer (like papillary or follicular) and has a BRAF V600E mutation
- You have already tried radioactive iodine treatment, or you can't have it
- You have tried a targeted therapy drug (like lenvatinib or sorafenib) and your cancer grew or didn't respond
- You have not had cabozantinib or a BRAF-targeted drug before for your thyroid cancer
- You are healthy enough to perform daily activities (ECOG score 0-2) and do not have serious heart or bleeding problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This trial tests whether giving targeted drugs before surgery can shrink advanced thyroid cancers that are hard to remove. It uses genetic test results to match you to a specific treatment arm, aiming to make surgery safer and more successful.
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
This Phase 1 trial studies whether targeted medicines (dabrafenib and trametinib) plus radiation can control an aggressive thyroid cancer with a specific BRAF gene change. It may help by attacking cancer cells that have this mutation and using focused radiation to improve tumor control.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests if a second course of targeted therapy (dabrafenib and trametinib) combined with chemotherapy can help people with a specific type of aggressive thyroid cancer (BRAF-positive anaplastic thyroid cancer) whose tumors stopped responding to initial targeted therapy.
Hear when a new Refractory Differentiated Thyroid Gland Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.